ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1036

Using the Oxford Classification in Assessing the Therapeutic Effects in IgA Nephropathy: A Secondary Analysis from a Randomized Clinical Trial

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Duan, Shuwei, Department of Nephrology, State Key Laboratory of Kidney Disease, Beijing, China
  • Cai, Guangyan, Chinese PLA Genaral Hospital, Beijing, BEIJING, China
  • Chen, Xiangmei, Chinese PLA General Hospital, Beijing, BEIJING, China

The Oxford Classification established a consensus on pathologic features that could predict the risks of progression of IgA nephropathy(IgAN). Clinically, histopathology is essential for both evaluating the severity of the lesions and guiding therapeutic strategies for IgAN. It remains a challenge whether or not Oxford Classification can guide therapeutic strategies. The aim of the analysis was to evaluate if the oxford classification can predict the therapeutic effects for patients receiving telmisartan and/or clopidogrel with/without leflunomide.


The multicentre, prospective, double-blind, double-dummy RCT was conducted between July 2010 and June 2012 in Beijing, China. The results were published in Chinese Medical Journal in 2016.
There were 162 cases, who were diagnosed in Chinese PLA General hospital, included in this secondary analysis. The complete or partial remission was defined as 24 hour proteinuria <0.3g or ≥30% reduction and stable kidney function. Stable kidney function was defined as increase in serum creatinine less than 26.4umol/L at week 24. The other was defined as ineffectiveness.
The logistical regression was used to analyse the relationship between the character of Oxford classification and the effect.


Multiple logistic regression analysis showed that both of 24 hour proteinuria≥1g (Odds Ratio(OR)=2.13, 95%CI 1.04-4.36) and taking leflunomide(OR=5.70, 95%CI 2.66-12.24) were the advantage factors. Only tubular atrophy/interstitial fibrosis >50% were the risk factor(OR=18%, 95%CI 8%-40%). Especially, we found that there were interaction between mesangial hypercellularity >0.5 and leflunomide.


This secondary analysis supports the oxford classification for IgAN has capacity to predict the therapeutic effects for patients receiving telmisartan with leflunomide. Mesangial hypercellularity >0.5 maybe the potential character of taking leflunomide.


  • Government Support - Non-U.S.